Overview
Analysis
Solutions
Complete
·Dec 1, 2024
The Core Insight

IgG's exceptional structural stability is an exploitable advantage

  • IgG antibodies feature 12+ disulfide bonds and rigid β-sheet architecture providing exceptional stability.
  • Caprylic acid at pH 4.5-5.0 destabilizes host cell proteins through hydrophobic core disruption while antibodies remain soluble.
  • This differential stability—exploited by plasma fractionation for 70+ years—transfers directly to recombinant antibodies.
Viability
Solvable
  • The chemistry is 70+ years proven in plasma fractionation.
  • Brodsky et al.
  • validated transfer to CHO antibodies.
  • The challenge is molecule-specific optimization and regulatory strategy, not fundamental science.
Key Decision

Is this for a new product/biosimilar or an approved product requiring process change? New products have clearer regulatory pathways for novel purification chemistry. Approved products may benefit more from incremental high-capacity resin improvements while developing precipitation platform for next molecule.

Solution Paths
01NEEDS VALIDATION

Caprylic Acid Precipitation + Single Polish

Transfer 70-year proven plasma chemistry to CHO antibodies. 55-70% cost reduction expected. What needs to be solved: molecule-specific aggregation screening.

02READY NOW

High-Capacity Protein A with Enhanced Clarification

MabSelect PrismA (70-80 g/L DBC) with polyelectrolyte flocculation. 40-55% cost reduction. What needs to be solved: process integration.

Recommendation
  1. Execute caprylic acid precipitation screening immediately—$30-50K experiment answers key question within 4-6 weeks.
  2. Plasma fractionation industry has employed this approach for 70 years; Brodsky's 2012 publication proves viability for CHO antibodies.
  3. Primary risk centers on molecule-specific aggregation; you'll know within one month whether your antibody tolerates conditions.
  4. Concurrently implement high-capacity resin + flocculation optimization as near-term win.
  5. This represents best-practice catch-up—not innovative, but low-risk, delivering 40-50% savings within 6-12 months while developing precipitation platform.
  6. For longer term, seriously evaluate chromatography-free precipitation train for next new product or biosimilar.
  7. Dairy industry purifies IgG at $2-5/kg using only precipitation.
  8. Regulatory acceptance of this approach in antibodies fundamentally reshapes biologics manufacturing economics.
  9. Elastin-like polypeptide and crystallization approaches, while intellectually elegant, require excessive upstream engineering or molecule-specific optimization for near-term impact.
  10. Maintain radar positioning for next-generation platform development.

By continuing, you agree to our use of cookies to improve your experience.